You just read:

TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

News provided by

Innovent Biologics, Inc.

May 13, 2020, 19:30 ET